Search by Title Article Topic - Any -AdvocacyAnnual Scientific MeetingAwardsBoard Certification ReviewCertificationClinical DocumentClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHF Research FoundationHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterIn The NewsIndustryJournal of Cardiac FailureLeadershipMembershipMentorshipNursingPartnersPatient ResourcePatient StoryPodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaStatementSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News Sep 3 2020 | Seeking Applications for Journal of Cardiac Failure, Editor-in-Chief HFSA News Journal of Cardiac Failure Read More Sep 2 2020 | ACC Seeks Comments on Updated Expert Consensus Decision Pathway For HF Treatment Optimization Practice News Read More Sep 2 2020 | Jardiance® reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25% in adults with and without diabetes who had heart failure with reduced ejection fraction Industry News Industry Read More Sep 1 2020 | Farxiga demonstrated unprecedented reduction in the risk of kidney failure and cardiovascular or renal death in patients with chronic kidney disease in the Phase III DAPA-CKD trial Industry News Industry Read More Aug 29 2020 | HFSA Announces Search for Editor-in-Chief for Journal of Cardiac Failure HFSA News Journal of Cardiac Failure Professional Development Read More Pagination First page « First Previous page ‹ Previous … Page 88 Page 89 Page 90 Page 91 Current page 92 Page 93 Page 94 Page 95 Page 96 … Next page Next › Last page Last »
Sep 3 2020 | Seeking Applications for Journal of Cardiac Failure, Editor-in-Chief HFSA News Journal of Cardiac Failure Read More
Sep 2 2020 | ACC Seeks Comments on Updated Expert Consensus Decision Pathway For HF Treatment Optimization Practice News Read More
Sep 2 2020 | Jardiance® reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25% in adults with and without diabetes who had heart failure with reduced ejection fraction Industry News Industry Read More
Sep 1 2020 | Farxiga demonstrated unprecedented reduction in the risk of kidney failure and cardiovascular or renal death in patients with chronic kidney disease in the Phase III DAPA-CKD trial Industry News Industry Read More
Aug 29 2020 | HFSA Announces Search for Editor-in-Chief for Journal of Cardiac Failure HFSA News Journal of Cardiac Failure Professional Development Read More
